A Phase 2 interventional study of Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. and Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV. in Invasive Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 13 sites in 2 countries. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-16.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Meningococcal Infections by Novartis — none open to participants now, none under way, none of them phase 3. Meningococcal Infections · Novartis.
Among the 60 studies in Meningococcal Infections by Novartis, this one is the 29th largest by enrollment of the 57 interventional ones that give a count, is one of 10 that started in 2011, is one of 21 in phase 2, and was the 39th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →None of the 60 studies in Meningococcal Infections by Novartis is open now. The open studies under Meningococcal Infections, anywhere →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 10 Years to 25 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 24 · Phase 3 30 · Phase 4 6
First in 2004; this study’s year is marked. 10 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 484 is close to the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 484 across the 57 interventional studies, 393 across the 3 observational. Of the 59 that completed or were terminated, 48 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 60 studies in Meningococcal Infections by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and immunogenicity of combination vaccines as compared to the reference vaccines
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this group received two doses of "Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine" plus Outer Membrane Vesicles (OMV) administered two months apart.
Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.
Subjects in this group received two doses of "Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine" plus one quarter dose of Outer Membrane Vesicles (qOMV) administered two months apart.
Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
Subjects in this group received two doses of "Meningococcal (group B) multicomponent recombinant adsorbed vaccine",administered two months apart.
Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
Subjects in this group received a dose of placebo followed by one dose of "Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine" administered two months later.
Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
Percentages of Subjects With a Seroresponse Against N.Meningitidis Serogroups A,C,W-135,Y, After Receiving Different Formulations of MenABCWY Combination Vaccine.
Non-inferiority of immune response of two doses of two different formulations of MenABCWY vaccine to a single dose of MenACWY vaccine as measured by the percentage of subjects with hSBA seroresponse against N.meningitidis serogroups A,C,W and Y. Seroresponse is defined as: 1. For subjects with a pre-vaccination hSBA titer \< 1:4, a post-vaccination hSBA titer ≥ 1:8; 2. For subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the prevaccination titer. Functional bactericidal antibodies directed against serogroups A,C,W,Y meningococci were measured with a serum bactericidal activity assay using human serum as the source of exogenous complement (hSBA).
Time frame: One month after the second vaccination (Day 91)
Desirability Index for Each Vaccine Group, Based on Immunogenicity and Reactogenicity Parameters.
The overall desirability index (DI) used to identify the optimal formulation of the combination vaccine was based on immunogenicity and reactogenicity parameters (on a scale of 0 to 1, with 0 for an undesirable response and 1 for a highly desirable response) as follows: Between-group ratios of hSBA GMTs were calculated, adjusted for prevaccination titer and center, against serogroups A, C, W, and Y (ABCWY+OMV group or ABCWY+qOMV group vs. Placebo/ACWY group) and against the 4 serogroup B test strains (ABCWY+OMV group or ABCWY+qOMV group vs. rMenB+OMV group). Reactogenicity was measured by the percentage of doses associated with severe local and systemic solicited AEs within 3 days following vaccination. Each immunogenicity and reactogenicity endpoint was assigned its own DI based on predefined desirability functions. The overall DI was calculated using the weighted geometric mean of the DI values of each of the ten parameters to derive an overall DI for each formulation.
Time frame: One month after the second vaccination (Day 91)
Percentages of Subjects With hSBA Titers ≥ 1:8 Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.
Percentages of subjects with hSBA titers ≥ 1:8 against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine or one dose of MenACWY vaccine.
Time frame: Day 1 and one month after second vaccination (Day 91)
The hSBA GMTs Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.
The hSBA GMTs against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine, or one dose of MenACWY vaccine.
Time frame: Day 1 and one month after the second vaccination (Day 91)
Percentages of Subjects With hSBA Titers ≥ 1:5 and ≥ 1:8 Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.
The percentages of subjects with hSBA titers ≥ 1:5 and ≥ 1:8 against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.
Time frame: Day 1 and one month after the second vaccination (Day 91)
Percentages of Subjects With at Least 4-fold Increase in hSBA Titers Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.
The percentages of subjects with at least 4-fold increase in hSBA titers against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine. 4-fold increase is defined as follows; for subjects with a prevaccination hSBA \< 1:2, a postvaccination hSBA ≥ 1:8, for subjects with a prevaccination hSBA ≥ 1:2, at least a 4-fold increase.
Time frame: One month after the second vaccination (Day 91)
The hSBA GMTs Against N.Meningitidis serogroupB, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.
The hSBA GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.
Time frame: Day 1 and one month after the second vaccination (Day 91)
The Geometric Mean Ratio of Post vs Pre Vaccination GMTs Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.
The geometric mean ratio (GMR) of post vaccination versus pre vaccination GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.
Time frame: One month after the second vaccination/prevaccination (Day 91/day 1)
The Number of Subjects Reporting Solicited Adverse Events After Receiving Any Vaccination in This Study.
The number of subjects reporting solicited local and systemic adverse events and other indicators of reactogenicity after vaccination with ABCWY+OMV, ABCWY+qOMV or rMenB+OMV or MenACWY.
Time frame: Day 1 through day 7 after any vaccination
The Number of Subjects Reporting Unsolicited Adverse Events After Receiving Any Vaccination in This Study.
The number of subjects reporting unsolicited AEs after vaccination with ABCWY+OMV, ABCWY+qOMV, rMenB+OMV or MenACWY.
Time frame: Throughout the study ( Day 1 to Day 241)
| Milestone | ABCWY+OMV | ABCWY+qOMV | rMenB +OMV | ACWY |
|---|---|---|---|---|
| Started | 120 | 121 | 122 | 121 |
| Completed | 103 | 100 | 109 | 107 |
| Not completed | 17 | 21 | 13 | 14 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 6 | 3 | 2 |
| Withdrew: Lost to follow-up | 15 | 14 | 8 | 10 |
| Withdrew: Inappropriate enrollment | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 1 |
Non-inferiority of immune response of two doses of two different formulations of MenABCWY vaccine to a single dose of MenACWY vaccine as measured by the percentage of subjects with hSBA seroresponse against N.meningitidis serogroups A,C,W and Y. Seroresponse is defined as: 1. For subjects with a pre-vaccination hSBA titer \< 1:4, a post-vaccination hSBA titer ≥ 1:8; 2. For subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the prevaccination titer. Functional bactericidal antibodies directed against serogroups A,C,W,Y meningococci were measured with a serum bactericidal activity assay using human serum as the source of exogenous complement (hSBA).
| Percentages of subjects | ABCWY+OMV | ABCWY+qOMV | ACWY |
|---|---|---|---|
| Men A | 90 (81 to 95) | 92 (83 to 97) | 73 (62 to 83) |
| Men C | 95 (89 to 99) | 93 (85 to 97) | 63 (51 to 74) |
| Men W-135 | 80 (69 to 88) | 84 (73 to 91) | 65 (52 to 77) |
| Men Y | 92 (83 to 97) | 90 (80 to 96) | 75 (62 to 85) |
The overall desirability index (DI) used to identify the optimal formulation of the combination vaccine was based on immunogenicity and reactogenicity parameters (on a scale of 0 to 1, with 0 for an undesirable response and 1 for a highly desirable response) as follows: Between-group ratios of hSBA GMTs were calculated, adjusted for prevaccination titer and center, against serogroups A, C, W, and Y (ABCWY+OMV group or ABCWY+qOMV group vs. Placebo/ACWY group) and against the 4 serogroup B test strains (ABCWY+OMV group or ABCWY+qOMV group vs. rMenB+OMV group). Reactogenicity was measured by the percentage of doses associated with severe local and systemic solicited AEs within 3 days following vaccination. Each immunogenicity and reactogenicity endpoint was assigned its own DI based on predefined desirability functions. The overall DI was calculated using the weighted geometric mean of the DI values of each of the ten parameters to derive an overall DI for each formulation.
| Desirability index | ABCWY+OMV | ABCWY+qOMV |
|---|---|---|
| Desirability Index for Each Vaccine Group, Based on Immunogenicity and Reactogenicity Parameters. | 0.306 | 0.325 |
Percentages of subjects with hSBA titers ≥ 1:8 against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine or one dose of MenACWY vaccine.
| Percentages of subjects | ABCWY+OMV | ABCWY+qOMV | ACWY |
|---|---|---|---|
| Men A (Day 1) | 8 (3 to 15) | 6 (2 to 13) | 1 (0.033 to 7) |
| Men A (Day 91) | 93 (86 to 97) | 95 (88 to 99) | 73 (62 to 83) |
| Men C (Day 1) | 35 (25 to 46) | 35 (25 to 46) | 32 (21 to 43) |
| Men C (Day 91) | 99 (94 to 100) | 100 (96 to 100) | 83 (73 to 91) |
| Men W-135 (Day 1) | 66 (55 to 76) | 58 (47 to 69) | 51 (39 to 64) |
| Men W-135 (Day 91) | 100 (95 to 100) | 100 (95 to 100) | 89 (79 to 96) |
| Men Y (Day 1) | 18 (11 to 28) | 15 (8 to 25) | 8 (3 to 17) |
| Men Y (Day 91) | 97 (89 to 100) | 97 (90 to 100) | 82 (70 to 90) |
The hSBA GMTs against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine, or one dose of MenACWY vaccine.
| Titers | ABCWY+OMV | ABCWY+qOMV | ACWY |
|---|---|---|---|
| Men A (Day 1) | 1.57 (1.28 to 1.92) | 1.32 (1.07 to 1.63) | 1.33 (1.08 to 1.65) |
| Men A (Day 91) | 71 (49 to 102) | 77 (53 to 111) | 45 (31 to 65) |
| Men C (Day 1) | 4.15 (3.02 to 5.69) | 3.72 (2.69 to 5.12) | 3.93 (2.84 to 5.45) |
| Men C (Day 91) | 214 (148 to 309) | 187 (129 to 272) | 55 (38 to 80) |
| Men W-135 (Day 1) | 14 (8.88 to 22) | 10 (6.45 to 16) | 6.58 (4.11 to 11) |
| Men W-135 (Day 91) | 239 (178 to 322) | 288 (214 to 389) | 65 (48 to 90) |
| Men Y (Day 1) | 2.01 (1.52 to 2.66) | 1.91 (1.43 to 2.53) | 1.52 (1.14 to 2.04) |
| Men Y (Day 91) | 149 (95 to 234) | 129 (83 to 201) | 46 (29 to 72) |
The percentages of subjects with hSBA titers ≥ 1:5 and ≥ 1:8 against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.
| Percentages of subjects | ABCWY+OMV | ABCWY+qOMV | rMenB +OMV |
|---|---|---|---|
| M14459 (Day 1; hSBA ≥1:5) | 9 (4 to 17) | 4 (1 to 10) | 5 (2 to 12) |
| M14459 (Day 91; hSBA ≥1:5) | 64 (53 to 74) | 71 (60 to 80) | 82 (72 to 89) |
| M01-0240364 (Day 1; hSBA ≥1:5) | 3 (1 to 9) | 14 (8 to 24) | 4 (1 to 11) |
| M01-0240364 (Day 91; hSBA ≥1:5) | 80 (70 to 88) | 80 (70 to 88) | 93 (86 to 98) |
| NZ 98/254 (Day 1; hSBA ≥1:5) | 3 (1 to 10) | 1 (0.03 to 6) | 3 (1 to 9) |
The percentages of subjects with at least 4-fold increase in hSBA titers against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine. 4-fold increase is defined as follows; for subjects with a prevaccination hSBA \< 1:2, a postvaccination hSBA ≥ 1:8, for subjects with a prevaccination hSBA ≥ 1:2, at least a 4-fold increase.
| Percentages of subjects | ABCWY+OMV | ABCWY+qOMV | rMenB+OMV |
|---|---|---|---|
| M14459 | 56 (45 to 67) | 62 (51 to 73) | 75 (65 to 83) |
| M01-0240364 | 79 (69 to 87) | 70 (59 to 79) | 88 (79 to 94) |
| NZ98/254 | 47 (36 to 58) | 48 (37 to 59) | 76 (66 to 84) |
| M07-0241084 | 28 (19 to 38) | 25 (16 to 36) | 42 (32 to 53) |
The hSBA GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.
| Titers | ABCWY+OMV | ABCWY+qOMV | rMenB +OMV |
|---|---|---|---|
| M14459 (Day 1) | 1.32 (1.09 to 1.59) | 1.15 (0.95 to 1.4) | 1.26 (1.04 to 1.53) |
| M14459 (Day 91) | 9.24 (6.19 to 14) | 11 (7.51 to 17) | 17 (11 to 25) |
| M01-0240364 (Day 1) | 1.08 (0.82 to 1.42) | 1.72 (1.29 to 2.28) | 1.14 (0.86 to 1.51) |
| M01-0240364 (Day 91) | 55 (33 to 93) | 48 (28 to 83) | 118 (69 to 202) |
| NZ 98/254 (Day 1) | 1.2 (1.03 to 1.39) | 1.1 (0.94 to 1.28) | 1.21 (1.04 to 1.42) |
| NZ 98/254 (Day 91) | 8.68 (5.91 to 13) | 7.88 (5.3 to 12) | 19 (13 to 27) |
| M07-0241084 (Day 1) | 2.55 (1.86 to 3.49) | 2.45 (1.76 to 3.4) | 2.13 (1.54 to 2.94) |
| M07-0241084 (Day 91) | 7.24 (5.4 to 9.71) | 6.26 (4.63 to 8.46) | 12 (8.83 to 16) |
The geometric mean ratio (GMR) of post vaccination versus pre vaccination GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.
| Ratio | ABCWY+OMV | ABCWY+qOMV | rMenB+OMV |
|---|---|---|---|
| M14459 | 7.32 (4.89 to 11) | 9.41 (6.19 to 14) | 14 (9.01 to 21) |
| M01-0240364 | 48 (27 to 83) | 30 (17 to 54) | 98 (56 to 173) |
| NZ 98/254 | 7.44 (5.06 to 11) | 6.91 (4.64 to 10) | 16 (11 to 23) |
| M07-0241084 | 2.94 (2.15 to 4.02) | 2.59 (1.88 to 3.58) | 5.16 (3.76 to 7.08) |
The number of subjects reporting solicited local and systemic adverse events and other indicators of reactogenicity after vaccination with ABCWY+OMV, ABCWY+qOMV or rMenB+OMV or MenACWY.
| Participants | ABCWY+OMV | ABCWY+qOMV | rMenB+OMV | ACWY |
|---|---|---|---|---|
| Injection site erythema | 57 | 53 | 72 | 30 |
| Injection site induration | 46 | 52 | 46 | 24 |
| Injection site pain | 98 | 96 | 107 | 50 |
| Chills | 18 | 21 | 29 | 12 |
| Nausea | 15 | 25 | 30 | 8 |
| Fatigue | 32 | 47 | 52 | 30 |
| Myalgia | 65 | 67 | 67 | 38 |
| Arthralgia | 20 | 23 | 25 | 7 |
| Headache | 37 | 40 | 53 | 29 |
| Rash | 6 | 8 | 4 | 6 |
| Loss of appetite | 17 | 22 | 24 | 12 |
| Fever ( >= 38C ) | 7 | 5 | 6 | 1 |
| Medically attended fever | 2 | 0 | 0 | 0 |
| Prophylactic use of antipyretic | 17 | 14 | 16 | 7 |
| Therapeutic use of antipyretic | 18 | 26 | 27 | 10 |
The number of subjects reporting unsolicited AEs after vaccination with ABCWY+OMV, ABCWY+qOMV, rMenB+OMV or MenACWY.
| Participants | ABCWY+OMV | ABCWY+qOMV | rMenB+OMV | ACWY |
|---|---|---|---|---|
| Any AEs (from day 1 to 30) | 36 | 36 | 45 | 31 |
| At least possibly related AEs (day 1 to 30) | 12 | 10 | 16 | 6 |
| Any AEs (day 31 to 60 or study termination) | 22 | 29 | 29 | 26 |
| At least poss.rel.AEs(day 31 to 60 or study term.) | 0 | 1 | 0 | 0 |
| Any AE from day 1 to 91 | 51 | 55 | 66 | 50 |
| At least poss.rel.AEs(day 1 to 91) | 13 | 10 | 16 | 6 |
| Medically attended AEs (day 92 to 241) | 26 | 24 | 30 | 31 |
| possibly related med.attend.AEs (day 92-241) | 0 | 0 | 0 | 0 |
| SAEs (Day 1 to Day 241) | 2 | 2 | 1 | 3 |
| Possibly/probably related SAEs | 0 | 0 | 0 | 0 |
| AEs leading to withdrawal (Day 1 to Day 241) | 0 | 0 | 2 | 0 |
| Deaths (Day 1 to Day 241) | 0 | 0 | 0 | 0 |
Percentages of Subjects With hSBA Titers ≥ 1:5 Against N.Meningitidis Serogroup B strains 44/76 and 5/99 at one month after second vaccination are calculated
| Percentage of subjects | ABCWY+OMV | ABCWY+qOMV | rMenB +OMV |
|---|---|---|---|
| 44/76- Baseline | 6 (2 to 12) | 7 (3 to 15) | 7 (2 to 14) |
| 44/76- 1 month after second dose | 100 (96 to 100) | 99 (94 to 100) | 98 (92 to 100) |
| 5/99- Baseline | 11 (6 to 20) | 15 (8 to 25) | 16 (9 to 25) |
| 5/99- 1 month after second dose | 99 (94 to 100) | 99 (94 to 100) | 98 (92 to 100) |
Collected over Solicited AEs were collected from Day 1to Day 7; unsolicited AEs and SAEs were collected throughout the study period (Day 1 to Day 241).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABCWY+OMV | — | 2/120 (1.7%) | 104/120 (86.7%) |
| ABCWY+qOMV | — | 2/120 (1.7%) | 104/120 (86.7%) |
| rMenB +OMV | — | 1/120 (0.8%) | 111/120 (92.5%) |
| ACWY | — | 3/109 (2.8%) | 87/109 (79.8%) |
| Event | ABCWY+OMV | ABCWY+qOMV | rMenB +OMV | ACWY |
|---|---|---|---|---|
| ABDOMINAL PAINGastrointestinal disorders | 0/120 | 0/120 | 0/120 | 1/109 |
| SPERMATOCELEReproductive system and breast disorders | 0/120 | 0/120 | 0/120 | 1/109 |
| SLEEP APNOEA SYNDROMERespiratory, thoracic and mediastinal disorders | 0/120 | 0/120 | 0/120 | 1/109 |
| GASTROENTERITISInfections and infestations | 1/120 | 0/120 | 0/120 | 0/109 |
| PERTUSSISInfections and infestations | 0/120 | 1/120 | 0/120 | 0/109 |
| PNEUMONIAInfections and infestations | 1/120 | 0/120 | 0/120 | 0/109 |
| URINARY TRACT INFECTIONInfections and infestations | 0/120 | 1/120 | 0/120 | 0/109 |
| CONVULSIONNervous system disorders | 0/120 | 0/120 | 1/120 | 0/109 |
| ABNORMAL BEHAVIOURPsychiatric disorders | 0/120 | 1/120 | 0/120 | 0/109 |
| Event | ABCWY+OMV | ABCWY+qOMV | rMenB +OMV | ACWY |
|---|---|---|---|---|
| Injection site PainGeneral disorders | 100/120 | 97/120 | 107/120 | 56/109 |
| Injection site ErythemaGeneral disorders | 59/120 | 53/120 | 72/120 | 32/109 |
| MyalgiaMusculoskeletal and connective tissue disorders | 65/120 | 67/120 | 67/120 | 39/109 |
| HeadacheNervous system disorders | 38/120 | 41/120 | 53/120 | 32/109 |
| FatigueGeneral disorders | 33/120 | 47/120 | 52/120 | 32/109 |
| Injection site IndurationGeneral disorders | 47/120 | 52/120 | 46/120 | 25/109 |
| NauseaGastrointestinal disorders | 15/120 | 25/120 | 31/120 | 9/109 |
| ChillsGeneral disorders | 19/120 | 22/120 | 29/120 | 12/109 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 22/120 | 24/120 | 25/120 | 8/109 |
| Decreased appetiteMetabolism and nutrition disorders | 17/120 | 22/120 | 24/120 | 12/109 |
Anaysis was done on the All Enrolled Population, ie, all subjects who signed an informed consent/assent, undergone screening procedure(s) and were randomized.
| Age, Continuous(years) | ABCWY+OMV | ABCWY+qOMV | rMenB +OMV | ACWY | Total |
|---|---|---|---|---|---|
| Mean | 14.7 ± 4.7 | 15.1 ± 4.9 | 15.3 ± 4.9 | 15.0 ± 5.1 | 15.0 ± 4.9 |
| Sex: Female, Male(Participants) | ABCWY+OMV | ABCWY+qOMV | rMenB +OMV | ACWY | Total |
|---|---|---|---|---|---|
| Female | 61 | 68 | 60 | 64 | 253 |
| Male | 59 | 53 | 62 | 57 | 231 |
The record gives a start of Aug 2011, a primary completion of Oct 2011 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.